RenovoRx, Inc. appointed Dr. Ramtin Agah to the newly created position of Executive Chairman, effective February 27, 2026, while he continues as Chief Medical Officer. The company entered into an amended employment agreement with Dr. Agah, which includes an annual base salary of $450,000 and eligibility for an annual discretionary bonus of up to 40% of his base salary.
Key takeaways
Dr. Ramtin Agah was appointed to the newly created position of Executive Chairman, effective February 27, 2026, while continuing as Chief Medical Officer.
The appointment was formalized by the board of directors on March 24, 2026.
Dr. Agah's amended employment agreement includes an annualized base salary of $450,000, based on working a minimum of 30 hours per week.
Dr. Agah is eligible for an annual discretionary bonus of up to 40% of his annualized base salary, with the first bonus payable in 2027 for 2026 performance.
Dr. Agah will be eligible to receive annual grants of options to purchase shares of the company's common stock and other compensatory awards as determined by the Compensation Committee.
The employment agreement amends, restates, and replaces the prior Consulting Agreement dated January 1, 2018, while the Amended and Restated Change in Control and Severance Agreement dated November 10, 2025, remains in effect.